{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:10:26Z","timestamp":1792156226668,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Master Carpenter J\u00f8rgen Holm and wife Elisa born Hansen\u2019s memorial trust","award":["20037"],"award-info":[{"award-number":["20037"]}]},{"name":"Medical specialist Heinrich Kopp\u2019s Foundation"},{"DOI":"10.13039\/100007403","name":"Dagmar Marshalls Foundation","doi-asserted-by":"crossref","award":["500020"],"award-info":[{"award-number":["500020"]}],"id":[{"id":"10.13039\/100007403","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001732","name":"The Danish National Research Foundation","doi-asserted-by":"crossref","award":["DNRF121"],"award-info":[{"award-number":["DNRF121"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Karen Elise Jensen Foundation"},{"name":"The Nordic Cancer Union"},{"DOI":"10.13039\/501100006304","name":"Aalborg University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006304","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To assess and describe chemotherapy-induced peripheral neuropathy (CIPN), a well-known complication to cancer treatment, using different methodologies in hematological patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients scheduled for treatment with vincristine, bortezomib, or lenalidomide were included in this longitudinal observational study. The patients were examined for CIPN before treatment (baseline), before each chemotherapy cycle, one month after end of treatment, and one year after baseline using patient-reported outcomes (Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Ntx-13 (FACT\/GOG-Ntx-13)) and clinician-assessed outcomes (the Common Terminology Criteria for Adverse Events (CTCAE) and the Total Neuropathy Score-clinical version (TNSc\u00a9)).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 23 patients with 171 examination visits were included between 2020 and 2022. Four patients were treated with vincristine, five with bortezomib, and fourteen with bortezomib and lenalidomide combined. Defining CIPN as a\u2009\u2265\u200910% decrease in the FACT\/GOG-Ntx-13, 11 patients (47.8%) developed CIPN during treatment and follow-up. CTCAE score for paresthesia increased from baseline throughout treatment until 1 month after the last treatment (p\u2009\u2264\u20090.045). Overall, the highest proportion of CIPN was present at cycle 3\u20134 and 1 month after last treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study describes the course of CIPN in patients treated with vincristine, bortezomib, or lenalidomide using both patient-reported and clinician-assessed outcomes. The highest proportion of CIPN was present at cycle 3\u20134 and 1 month after treatment, at which timepoints clinicians must be especially aware of CIPN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Registered at Clinicaltrials.gov (Trial Registration Number: NCT04393363) on March 19, 2020.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09282-3","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T21:06:31Z","timestamp":1740603991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9338-997X","authenticated-orcid":false,"given":"Eva Futtrup","family":"Maksten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten Dahl","family":"M\u00f8rch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse Hjort","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Hay","family":"Kragholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille From","family":"Blindum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Runason","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Ejskjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dybk\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarec C.","family":"El-Galaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Tang","family":"Severinsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"9282_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15\u201349. https:\/\/doi.org\/10.1053\/j.seminoncol.2005.12.010","journal-title":"Semin Oncol"},{"key":"9282_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3322\/caac.21204","volume":"63","author":"SB Park","year":"2013","unstructured":"Park SB, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63:419\u2013437. https:\/\/doi.org\/10.3322\/caac.21204","journal-title":"CA Cancer J Clin"},{"key":"9282_CR3","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 32:1941\u20131967. https:\/\/doi.org\/10.1200\/JCO.2013.54.0914","journal-title":"J Clin Oncol"},{"key":"9282_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","volume":"121","author":"JLM Jongen","year":"2015","unstructured":"Jongen JLM, Broijl A, Sonneveld P (2015) Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neurooncol 121:229\u2013237. https:\/\/doi.org\/10.1007\/s11060-014-1632-x","journal-title":"J Neurooncol"},{"key":"9282_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/J.PAIN.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. PAIN\u00ae 155:2461\u20132470. https:\/\/doi.org\/10.1016\/J.PAIN.2014.09.020","journal-title":"PAIN\u00ae"},{"key":"9282_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/clpt.2011.115","volume":"90","author":"DR Pachman","year":"2011","unstructured":"Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377\u2013387. https:\/\/doi.org\/10.1038\/clpt.2011.115","journal-title":"Clin Pharmacol Ther"},{"key":"9282_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess J, Ferdousi M, Gosal D et al (2021) Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther 9:385\u2013450. https:\/\/doi.org\/10.1007\/s40487-021-00168-y","journal-title":"Oncol Ther"},{"key":"9282_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1188\/13.CJON.138-144","volume":"17","author":"C Tofthagen","year":"2013","unstructured":"Tofthagen C, Visovsky CM, Hopgood R (2013) Chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 17:138\u2013144. https:\/\/doi.org\/10.1188\/13.CJON.138-144","journal-title":"Clin J Oncol Nurs"},{"key":"9282_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/01.NNR.0000289503.22414.79","volume":"56","author":"MA Bakitas","year":"2007","unstructured":"Bakitas MA (2007) Background noise. Nurs Res 56:323\u2013331. https:\/\/doi.org\/10.1097\/01.NNR.0000289503.22414.79","journal-title":"Nurs Res"},{"key":"9282_CR10","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1188\/10.CJON.E22-E28","volume":"14","author":"C Tofthagen","year":"2010","unstructured":"Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14:E22\u2013E28. https:\/\/doi.org\/10.1188\/10.CJON.E22-E28","journal-title":"Clin J Oncol Nurs"},{"key":"9282_CR11","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38:3325\u20133348. https:\/\/doi.org\/10.1200\/JCO.20.01399","journal-title":"J Clin Oncol"},{"key":"9282_CR12","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO\u2013EONS\u2013EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306\u20131319. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.003","journal-title":"Ann Oncol"},{"key":"9282_CR13","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1007\/s00520-020-05796-0","volume":"29","author":"Y-J Wang","year":"2021","unstructured":"Wang Y-J, Chan Y-N, Jheng Y-W et al (2021) Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study. Support Care Cancer 29:2959\u20132971. https:\/\/doi.org\/10.1007\/s00520-020-05796-0","journal-title":"Support Care Cancer"},{"key":"9282_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","volume":"19","author":"A Molassiotis","year":"2019","unstructured":"Molassiotis A, Cheng HL, Lopez V et al (2019) Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19:132. https:\/\/doi.org\/10.1186\/s12885-019-5302-4","journal-title":"BMC Cancer"},{"key":"9282_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","volume":"13","author":"V Chaudhry","year":"2008","unstructured":"Chaudhry V, Cornblath DR, Polydefkis M et al (2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 13:275\u2013282. https:\/\/doi.org\/10.1111\/j.1529-8027.2008.00193.x","journal-title":"J Peripher Nerv Syst"},{"key":"9282_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.clml.2017.06.035","volume":"17","author":"A Lakshman","year":"2017","unstructured":"Lakshman A, Modi M, Prakash G et al (2017) Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction. Clin Lymphoma Myeloma Leuk 17:513-519.e1. https:\/\/doi.org\/10.1016\/j.clml.2017.06.035","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"9282_CR17","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113\u20133120. https:\/\/doi.org\/10.1200\/JCO.2005.04.7779","journal-title":"J Clin Oncol"},{"key":"9282_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","volume":"86","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Mateos MV, Richardson PG et al (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86:23\u201331. https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01533.x","journal-title":"Eur J Haematol"},{"key":"9282_CR19","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1016\/j.clml.2022.07.002","volume":"22","author":"A Major","year":"2022","unstructured":"Major A, Jakubowiak A, Derman B (2022) Longitudinal real-world neuropathy and patient-reported outcomes with bortezomib and lenalidomide in newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 22:e1000\u2013e1008. https:\/\/doi.org\/10.1016\/j.clml.2022.07.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"9282_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1159\/000512165","volume":"144","author":"H Nahi","year":"2021","unstructured":"Nahi H, Walinder G, Patel V et al (2021) Burden of treatment-induced peripheral neuropathy in patients with multiple myeloma in Sweden. Acta Haematol 144:519\u2013527. https:\/\/doi.org\/10.1159\/000512165","journal-title":"Acta Haematol"},{"key":"9282_CR21","first-page":"741","volume":"13","author":"EA Calhoun","year":"2003","unstructured":"Calhoun EA, Welshman EE, Chang C-H et al (2003) Psychometric evaluation of the functional assessment of cancer therapy\/gynecologic oncology group-neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13:741\u2013748","journal-title":"Int J Gynecol Cancer"},{"key":"9282_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","volume":"17","author":"HQ Huang","year":"2007","unstructured":"Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17:387\u2013393. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.00794.x","journal-title":"Int J Gynecol Cancer"},{"key":"9282_CR23","doi-asserted-by":"publisher","unstructured":"Ajewole VB, Cox JE, Swan JT et al (2019) Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study. Support Care Cancer 1\u201312. https:\/\/doi.org\/10.1007\/s00520-019-05006-6","DOI":"10.1007\/s00520-019-05006-6"},{"key":"9282_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/onco.13697","volume":"26","author":"HC Timmins","year":"2021","unstructured":"Timmins HC, Li T, Trinh T et al (2021) Weekly paclitaxel-induced neurotoxicity in breast cancer: outcomes and dose response. Oncologist 26:366\u2013374. https:\/\/doi.org\/10.1002\/onco.13697","journal-title":"Oncologist"},{"key":"9282_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176\u2013181. https:\/\/doi.org\/10.1016\/S1053-4296(03)00031-6","journal-title":"Semin Radiat Oncol"},{"key":"9282_CR26","unstructured":"National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm.\u00a0Accessed 22 Nov 2019"},{"key":"9282_CR27","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","volume":"53","author":"DR Cornblath","year":"1999","unstructured":"Cornblath DR, Chaudhry V, Carter K et al (1999) Total neuropathy score: validation and reliability study. Neurology 53:1660\u20131660. https:\/\/doi.org\/10.1212\/WNL.53.8.1660","journal-title":"Neurology"},{"key":"9282_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","volume":"11","author":"G Cavaletti","year":"2006","unstructured":"Cavaletti G, Jann S, Pace A et al (2006) Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11:135\u2013141. https:\/\/doi.org\/10.1111\/j.1085-9489.2006.00078.x","journal-title":"J Peripher Nerv Syst"},{"key":"9282_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","volume":"12","author":"G Cavaletti","year":"2007","unstructured":"Cavaletti G, Frigeni B, Lanzani F et al (2007) The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the national cancer institute-common toxicity scale. J Peripher Nerv Syst 12:210\u2013215. https:\/\/doi.org\/10.1111\/j.1529-8027.2007.00141.x","journal-title":"J Peripher Nerv Syst"},{"key":"9282_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1188\/08.ONF.96-102","volume":"35","author":"EML Smith","year":"2008","unstructured":"Smith EML, Beck SL, Cohen J (2008) The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 35:96\u2013102. https:\/\/doi.org\/10.1188\/08.ONF.96-102","journal-title":"Oncol Nurs Forum"},{"key":"9282_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/J.JBI.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R et al (2009) Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377\u2013381. https:\/\/doi.org\/10.1016\/J.JBI.2008.08.010","journal-title":"J Biomed Inform"},{"key":"9282_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"9282_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2105\/AJPH.86.5.726","volume":"86","author":"M Aickin","year":"1996","unstructured":"Aickin M, Gensler H (1996) Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 86:726\u2013728. https:\/\/doi.org\/10.2105\/AJPH.86.5.726","journal-title":"Am J Public Health"},{"key":"9282_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur MJ, Stuart EA, Frangakis C, Leaf PJ (2011) Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 20:40\u201349. https:\/\/doi.org\/10.1002\/mpr.329","journal-title":"Int J Methods Psychiatr Res"},{"key":"9282_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2307\/1391390","volume":"4","author":"DB Rubin","year":"1986","unstructured":"Rubin DB (1986) Statistical matching using file concatenation with adjusted weights and multiple imputations. J Bus Econ Stat 4:87. https:\/\/doi.org\/10.2307\/1391390","journal-title":"J Bus Econ Stat"},{"key":"9282_CR36","first-page":"367","volume":"54","author":"TR Ten","year":"2018","unstructured":"Ten TR, Kunselman AR, Pulkstenis EP et al (2018) Mixed effects logistic regression models for longitudinal binary response data with informative drop-out. Biometrics 54:367\u2013383","journal-title":"Biometrics"},{"key":"9282_CR37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdt409","volume":"25","author":"P Alberti","year":"2014","unstructured":"Alberti P, Rossi E, Cornblath DR et al (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol Off J Eur Soc Med Oncol 25:257\u2013264. https:\/\/doi.org\/10.1093\/annonc\/mdt409","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"9282_CR38","doi-asserted-by":"publisher","unstructured":"Nyrop KA, Deal AM, Reeder-Hayes KE et al (2019) Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer 2945\u20132954. https:\/\/doi.org\/10.1002\/cncr.32175","DOI":"10.1002\/cncr.32175"},{"key":"9282_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","volume":"15","author":"KA Griffith","year":"2010","unstructured":"Griffith KA, Merkies ISJ, Hill EE, Cornblath DR (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15:314\u2013325. https:\/\/doi.org\/10.1111\/j.1529-8027.2010.00292.x","journal-title":"J Peripher Nerv Syst"},{"key":"9282_CR40","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1188\/17.ONF.E111-E123","volume":"44","author":"H Haryani","year":"2017","unstructured":"Haryani H, Fetzer S, Wu C-L, Hsu Y-Y (2017) Chemotherapy-induced peripheral neuropathy assessment tools: a systematic review. Oncol Nurs Forum 44:E111\u2013E123. https:\/\/doi.org\/10.1188\/17.ONF.E111-E123","journal-title":"Oncol Nurs Forum"},{"key":"9282_CR41","doi-asserted-by":"publisher","first-page":"E660","DOI":"10.1212\/WNL.0000000000012300","volume":"97","author":"P Alberti","year":"2021","unstructured":"Alberti P, Bernasconi DP, Cornblath DR et al (2021) Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity. Neurology 97:E660\u2013E672. https:\/\/doi.org\/10.1212\/WNL.0000000000012300","journal-title":"Neurology"},{"key":"9282_CR42","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJM199805283382207","volume":"338","author":"AH Ropper","year":"1998","unstructured":"Ropper AH, Gorson KC (1998) Neuropathies associated with paraproteinemia. N Engl J Med 338:1601\u20131607","journal-title":"N Engl J Med"},{"key":"9282_CR43","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3109\/10428194.2011.598253","volume":"52","author":"P Malhotra","year":"2011","unstructured":"Malhotra P, Choudhary PP, Lal V et al (2011) Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis. Leuk Lymphoma 52:2135\u20132138. https:\/\/doi.org\/10.3109\/10428194.2011.598253","journal-title":"Leuk Lymphoma"},{"key":"9282_CR44","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/bmj.324.7335.466","volume":"324","author":"RAC Hughes","year":"2002","unstructured":"Hughes RAC (2002) Regular review: peripheral neuropathy. BMJ 324:466\u2013469. https:\/\/doi.org\/10.1136\/bmj.324.7335.466","journal-title":"BMJ"},{"key":"9282_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cnr2.1577","volume":"5","author":"F van Haren","year":"2022","unstructured":"van Haren F, van den Heuvel S, Ligtenberg M et al (2022) Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes. Cancer Rep 5:1\u20139. https:\/\/doi.org\/10.1002\/cnr2.1577","journal-title":"Cancer Rep"},{"key":"9282_CR46","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1529-8027.2011.00351.x","volume":"16","author":"B Frigeni","year":"2011","unstructured":"Frigeni B, Piatti M, Lanzani F et al (2011) Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 16:228\u2013236. https:\/\/doi.org\/10.1111\/j.1529-8027.2011.00351.x","journal-title":"J Peripher Nerv Syst"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09282-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09282-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09282-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:29:49Z","timestamp":1742002189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09282-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9282"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09282-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"24 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by The North Denmark Region Committee\u00a0on Health Research Ethics (N-20190068) and registered at Clinicaltrials.gov (Trial Registration Number: NCT04393363) on March 19, 2020, and in the research registry of the North Denmark Region (2020\u2013081). This study was conducted in accordance with the principles of the Declaration of Helsinki and informed consent regarding participation and publishing of the collected data was obtained from all patients included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}